XTL Biopharmaceuticals XTLB Stock
XTL Biopharmaceuticals Price Chart
XTL Biopharmaceuticals XTLB Financial and Trading Overview
| XTL Biopharmaceuticals stock price | 2.87 USD |
| Previous Close | 2.81 USD |
| Open | 2.83 USD |
| Bid | 1.93 USD x 200 |
| Ask | 3.68 USD x 200 |
| Day's Range | 2.76 - 2.85 USD |
| 52 Week Range | 2.01 - 10.28 USD |
| Volume | 3.25K USD |
| Avg. Volume | 89.48K USD |
| Market Cap | 6.81M USD |
| Beta (5Y Monthly) | 0.461 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.36 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
XTLB Valuation Measures
| Enterprise Value | 6.85M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | 2.27 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -5.414 |
Trading Information
XTL Biopharmaceuticals Stock Price History
| Beta (5Y Monthly) | 0.461 |
| 52-Week Change | -58.77% |
| S&P500 52-Week Change | 18.32% |
| 52 Week High | 10.28 USD |
| 52 Week Low | 2.01 USD |
| 50-Day Moving Average | 2.63 USD |
| 200-Day Moving Average | 3.13 USD |
XTLB Share Statistics
| Avg. Volume (3 month) | 89.48K USD |
| Avg. Daily Volume (10-Days) | 3.83K USD |
| Shares Outstanding | 2.46M |
| Float | 1.5M |
| Short Ratio | 0.19 |
| % Held by Insiders | 38.46% |
| % Held by Institutions | 3.07% |
| Shares Short | 36.17K |
| Short % of Float | 1.95% |
| Short % of Shares Outstanding | 1.46% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:4 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | December 31, 2025 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -21.010% |
| Return on Equity (ttm) | -29.29% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -1266000 USD |
| Net Income Avi to Common (ttm) | -759000 USD |
| Diluted EPS (ttm) | -0.36 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 76K USD |
| Total Cash Per Share (mrq) | 0.03 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.395 |
| Book Value Per Share (mrq) | 0 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -1025000 USD |
| Levered Free Cash Flow (ttm) | -2116000 USD |
Profile of XTL Biopharmaceuticals
| Country | United States |
| State | N/A |
| City | Herzliya |
| Address | 85 Medinat Hayehudim St. |
| ZIP | 4676670 |
| Phone | 972 5 4228 8897 |
| Website | https://www.xtlbio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 4 |
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Herzliya, Israel.
Q&A For XTL Biopharmaceuticals Stock
What is a current XTLB stock price?
XTL Biopharmaceuticals XTLB stock price today per share is 2.87 USD.
How to purchase XTL Biopharmaceuticals stock?
You can buy XTLB shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for XTL Biopharmaceuticals?
The stock symbol or ticker of XTL Biopharmaceuticals is XTLB.
Which industry does the XTL Biopharmaceuticals company belong to?
The XTL Biopharmaceuticals industry is Biotechnology.
How many shares does XTL Biopharmaceuticals have in circulation?
The max supply of XTL Biopharmaceuticals shares is 2.46M.
What is XTL Biopharmaceuticals Price to Earnings Ratio (PE Ratio)?
XTL Biopharmaceuticals PE Ratio is now.
What was XTL Biopharmaceuticals earnings per share over the trailing 12 months (TTM)?
XTL Biopharmaceuticals EPS is -0.36 USD over the trailing 12 months.
Which sector does the XTL Biopharmaceuticals company belong to?
The XTL Biopharmaceuticals sector is Healthcare.
XTL Biopharmaceuticals XTLB included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26413.36 USD — |
-0.65
|
6.99B USD — | 26393.65 USD — | 26739 USD — | — - | 6.99B USD — |
|
US Tech Composite Total Return
XCMP
US
|
32526.02 USD — |
-0.83
|
— — | 32507.6 USD — | 32989.36 USD — | — - | — — |
|
US Tech Capital Market Composite
RCMP
US
|
140.4 USD — |
-0.63
|
— — | 140.31 USD — | 142.62 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1268.04 USD — |
+0.34
|
— — | 1260.71 USD — | 1278.44 USD — | — - | — — |
- {{ link.label }} {{link}}
